We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00978757
Recruitment Status : Completed
First Posted : September 17, 2009
Results First Posted : January 18, 2010
Last Update Posted : January 15, 2019
Sponsor:
Information provided by (Responsible Party):
FRANCISCO CARLOS BONOFIGLIO, Hospital Italiano de Buenos Aires

Brief Summary:
The purpose of this study is to determine whether ketamine is effective to inhibit interleukin 6 synthesis in hepatic resections requiring temporary porto-arterial occlusion.

Condition or disease Intervention/treatment Phase
Hepatectomy Drug: Ketamine Other: Placebo Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion
Study Start Date : June 2001
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ketamine
Ketamine: 0.25 mg/kg, intravenously, one dose.
Drug: Ketamine
Ketamine: 0.25 mg/kg, intravenously, one dose.
Other Name: Ketamine commercially available - FADA Pharma

Placebo Comparator: Placebo
Placebo: saline solution
Other: Placebo
saline solution
Other Name: Normal saline




Primary Outcome Measures :
  1. The Effect of Ketamine on Interleukin 6 (IL-6) Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion (Pringle Maneuver) [ Time Frame: Plasma concentration of IL-6 levels were obtained prior to surgery, upon placement of the first intravenous ]
    As an outcome, Interleukin 6 (IL-6) was measured in plasma concentration of hepatic resections requiring temporary porto-arterial occlusion patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 21 or older
  • Planned liver resection with Pringle maneuver lasting 30-60 minutes

Exclusion Criteria:

  • Chronic illness requiring corticosteroids
  • Cirrhosis
  • Hemodynamic instability prior to surgery
  • Diabetes
  • Sepsis
  • Surgical interventions or chemotherapy treatments within the past 30 days
  • Pregnancy
  • Illnesses that could potentially affect the hepatic circulation
  • Arterial hypertension
  • Ocular hypertension
  • Allergy to ketamine
  • Preoperative portal embolization
  • Radiofrequency ablation
  • Patients requiring emergency surgeries

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00978757


Locations
Layout table for location information
Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma de Buenos Aires, Argentina, 1181
Sponsors and Collaborators
Hospital Italiano de Buenos Aires
Investigators
Layout table for investigator information
Principal Investigator: Francisco C Bonofiglio, MD PhD Hospital Italiano of Buenos Aires, Argentina
Layout table for additonal information
Responsible Party: FRANCISCO CARLOS BONOFIGLIO, Anesthesiologist, Hospital Italiano de Buenos Aires
ClinicalTrials.gov Identifier: NCT00978757    
Other Study ID Numbers: IRB#556
First Posted: September 17, 2009    Key Record Dates
Results First Posted: January 18, 2010
Last Update Posted: January 15, 2019
Last Verified: March 2018
Keywords provided by FRANCISCO CARLOS BONOFIGLIO, Hospital Italiano de Buenos Aires:
hepatectomy
IL 6
organ failure
ketamine
Pringle
Additional relevant MeSH terms:
Layout table for MeSH terms
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action